D. Mero
Growth at reasonable price, healthcare, newsletter provider

Sanuwave May Be Able To Satisfy Investor Appetite For A Diabetic Foot Ulcer Treatment

(Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.)

Optimism in the diabetic foot ulcer sector has accelerated due to the robust results of various treatments undergoing clinical trials. On August 13th, Osiris Therapeutics (NASDAQ:OSIR) doubled in price on the news that Grafix, its stem-cell treatment for chronic diabetic foot ulcers (DFU), achieved overwhelmingly effective results in Phase IV studies. The attention generated by this catalyst spilled over to Sanuwave (OTCQB:SNWV), a development stage biotech that is also targeting DFU with its shockwave-based technology device dermaPACE. Following the release, Sanuwave price surged 13% on volume 10x the three month average, a daily capacity the company had not...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details